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Deciphering the genetic basis of human diseases is an important goal of biomedical research. On the
basis of the assumption that phenotypically similar diseases are caused by functionally related
genes, we propose a computational framework that integrates human protein–protein interactions,
disease phenotype similarities, and known gene–phenotype associations to capture the complex
relationships between phenotypes and genotypes. We develop a tool named CIPHER to predict and
prioritize disease genes, and we show that the global concordance between the human protein
network and the phenotype network reliably predicts disease genes. Our method is applicable to
genetically uncharacterized phenotypes, effective in the genome-wide scan of disease genes, and
also extendable to explore gene cooperativity in complex diseases. The predicted genetic landscape
of over 1000 human phenotypes, which reveals the global modular organization of phenotype–
genotype relationships. The genome-wide prioritization of candidate genes for over 5000 human
phenotypes, including those with under-characterized disease loci or even those lacking known
association, is publicly released to facilitate future discovery of disease genes.
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Introduction
Theidentiﬁcationofgenesresponsibleforspeciﬁcdiseaseshas
long been one of the major tasks in the study of human
genetics. Traditional gene-mapping approaches, such as
linkage analysis and association studies (Botstein and Risch,
2003), have been demonstrating remarkable success in this
ﬁeld. Family-based linkage analysis is able to associate
diseases with speciﬁc genomic regions. These regions are
often large, containing tens or even hundreds of genes, for
which experimental examination of causative mutations are
expensive and laborious. In contrast, candidate association
studies work well when applied to a set of carefully selected
functional candidate genes that have clear biological relation
to the disease. However, the selection of functional candidates
is not straightforward and is often limited by the scope of
experts. Indeed, the prioritization of positional candidates
from linkage analysis and the selection of functional candi-
dates for association studies have been translated into a need
forcomputationalmethodstoassessthesusceptibilityofgenes
to diseases on the basis of functions of genes.
With the fast accumulation of functional genomics data,
computational methods based on gene functions have
augmented or even supplanted traditional gene-mapping
approaches (Botstein and Risch, 2003; McCarthy et al, 2003).
These computational methods are largely based on the
similarity of characteristics of disease genes, including
sequence features (Adie et al, 2005; Aerts et al, 2006),
expression patterns (van Driel et al, 2003; Aerts et al, 2006;
Franke et al, 2006), functional annotations (Freudenberg and
Propping, 2002; Perez-Iratxeta et al, 2002; Turner et al, 2003;
Aerts et al, 2006; Franke et al, 2006), literature descriptions
(van Driel et al, 2003; Aerts et al, 2006; Li et al, 2006; Gaulton
et al, 2007), physical interactions (Aerts et al, 2006; Franke
et al, 2006; Oti et al, 2006), and many others (see review of Oti
and Brunner, 2007).
Typically, with these features available, a method for
prioritizing disease genes computes a score quantifying
the association between a gene and a disease, and then uses
the computed scores to rank the candidates and select
plausible susceptibility genes. However, various factors, such
as the pleiotropy of genes, the interactions among genes, the
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ary between different diseases, as well as the incompleteness
and false-positive data sources, might prevent the direct
inference of single gene–disease association (van Heyningen
and Yeyati, 2004).
With the development of systems biology, studies have
shownthatphenotypicallysimilardiseasesareoftencausedby
functionally related genes, being referred to as the modular
nature of human genetic diseases (Oti and Brunner, 2007; Oti
et al, 2008). This modularity, as recently supported by various
reports (Brunner and van Driel, 2004; Gandhi et al, 2006; Lim
et al, 2006; van Driel et al, 2006; Goh et al, 2007; Lage et al,
2007; Wagner et al, 2007; Wood et al, 2007), suggests that
causative genes for the same or phenotypically similar
diseases may generally reside in the same biological module,
either a protein complex (Lage et al, 2007), a pathway (Wood
et al, 2007), or a subnetwork of protein interactions (Lim et al,
2006). Aside from human disease, recent large-scale studies in
yeast (Fraser and Plotkin, 2007; McGary et al, 2007) and worm
(Lee et al, 2008) also support the idea that genes sharing
mutant phenotype are tightly linked in the network.
Withthisunderstanding,wereasonthatthismodularnature
implies a positive correlation between gene–gene relatedness
and phenotype–phenotype similarity. It is interesting to see
whether this second-order association between gene and
phenotype can be quantiﬁed for predicting disease genes. On
the basis of this notion, we build a regression model that can
explain phenotype similarity by gene closeness (topological
proximityinmolecularinteractionnetwork).Weshowthatthe
correlation between phenotype similarities and gene close-
ness, deﬁned by the concordance score, is a strong and robust
predictor of disease genes. With the use of this score, we
propose a new method, CIPHER (Correlating protein Interac-
tion network and PHEnotype network to pRedict disease
genes), to prioritize candidate genes and to explore gene
cooperative behavior in human disease. Our method success-
fully ranks known disease genes at top 1 in 709 out of 1444
linkage intervals, and we demonstrate its effectiveness in
prioritizing candidate genes for diseases without known
genetic basis by genome-wide scan of disease genes. The high
accuracyofourmethodanditsabilitytoperformgenome-wide
scan has enabled us to predict a comprehensive genetic
landscape of more than 5000 human phenotypes.
Results
Principles of CIPHER
CIPHER assumes that two genes closer to each other in a
molecular interaction network may often lead to more similar
phenotypes. The assumption is formulated into a regression
modelfromwhichwederiveascoretoassesshowlikelyagene
may be involved in a speciﬁc phenotype. The score, called the
concordance score, is calculated across the entire phenotype
network and protein network, measuring the general con-
cordance between the phenotype similarities and the func-
tional genetic relatedness of disease genes.
To build such a regression model, ideally one needs (1) a
complete set of standardized phenotypes and the quantiﬁed
similarities between those phenotypes, (2) a reliable and
complete set of physical interactions between proteins of
human genes, and (3) a complete list of known disease gene–
phenotype associations. In this study, a disease-related pheno-
type can be operationally interpreted as a textual description of
a disease’s detectable outward manifestations, and for our
study, we use the text records from the OMIM database
(McKusick, 2007). Similarity between two phenotypes quanti-
ﬁes the overlap of their OMIM descriptions and is calculated
through text mining (van Driel et al, 2006). Protein–protein
interactions (PPIs) are collected from a manually curated PPI
database called HPRD (Peri et al, 2003). Disease gene–pheno-
type associations are obtained from the OMIM database.
Although none of the data sets are currently complete, they
are comprehensive enough as will be shown below.
The scoring scheme of CIPHER is illustrated in Figure 1.
Givenaquery phenotypeanda setofcandidate genes,CIPHER
Figure 1 Scoring scheme of CIPHER. First, the human phenotype network, protein network, and gene–phenotype network are assembled into an integrated network.
Then, to score a particular phenotype–gene pair (p, g), the phenotype similarity proﬁle for p is extracted and the gene closeness proﬁle for g is computed from the
integrated network. Finally, the linear correlation of the two proﬁles is calculated and assigned as the concordance score between the phenotype p and the gene g.
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network, and protein network into a single network. Then, the
phenotype similarity scores between the query phenotype and
all phenotypes are extracted directly from the phenotype
network,formingthesimilarityproﬁleofthequeryphenotype,
and the topological distances from the candidate gene to all
knowndiseasegenesin theprotein networkarecalculatedand
grouped according to phenotypes they belong to, composing
the closeness proﬁle of the candidate gene. Third, with the use
of a linear regression model, the correlation between the
closeness proﬁle and similarity proﬁle is calculated and
assigned as the concordance score for each candidate gene.
Finally, all candidates are ranked on the basis of the scores
received.
We explore two deﬁnitions of topological distance on the
basis of two different neighborhood systems: shortest path
(SP)anddirectneighbor(DN).ThetwoversionsofCIPHERare
termed CIPHER-SP and CIPHER-DN, respectively. See the
section of Materials and methods for more details of the data
sources and the model.
Performance of CIPHER
To examine how well the concordance score reﬂects the
biological truth, we assess CIPHER’s ability to uncover known
disease genes. Each of the known gene–phenotype association
is taken as one test case, and for each case we generate a set of
genes as the negative control (note that some of them may be
true disease genes yet to be discovered). We then calculate the
concordance score for each test gene, and rank the test genes
according to the score. If the known disease gene is ranked as
top 1, we consider it a successful prediction, and we deﬁne the
precision as the proportion of successful predictions among all
predictions.Wesetathresholdandonlymakepredictionwhen
thehighestscoreofalltestgenesinacaseisnolessthanit,and
deﬁne recall as the fraction of true disease genes predicted
among all disease genes. An equivalent deﬁnition has been
used before (Lage et al, 2007).
We test our method on three types of control sets: artiﬁcial
linkage interval, random control, and the whole genome.
To simulate the real-life situation in which one or more
susceptible linkage interval(s) rather than speciﬁc genes have
been identiﬁed by linkage analysis, a benchmark test on
artiﬁcial linkage intervals around the known disease genes is
generally adopted (Perez-Iratxeta et al, 2002; Franke et al,
2006; Lage et al, 2007). We take a total of 108 genes upstream
and downstream of the known disease gene as controls, to
simulate the average size of linkage intervals in OMIM
morbidmap (Lage et al, 2007). A large-scale leave-one-out
cross-validation (see Materials and methods) shows CIPHER-
SPcan at least rank known disease genes as top 1 in 709 out of
1444 test cases, achieving a precision of 0.49 and a recall of
0.49. For high-scoring candidates, the precision can approach
0.67 while maintaining a high recall of 0.31 (Figure 2). For
CIPHER-DN, the precision is even higher, varying from 0.53 to
0.73.
It should be noticed that such a benchmarking might be
artiﬁcially biased toward better characterized genes, because
test genes without PPIs at the moment will be ranked at the
tail. To better assess the prediction power, we conduct a cross-
validation on random control. In total, 99 genes are sampled
from the protein network with equal probability to simulate a
fully characterized interval in which all genes have PPIs in the
protein network. The leave-one-out cross-validation shows
that CIPHER-SP successfully ranks 643 causative genes at top 1,
yielding a precision of 0.445. These results show that the
performance of CIPHER on random control is only slightly
lower than that on artiﬁcial intervals, revealing that CIPHER is
not biased toward better characterized genes.
We also examine the performance of CIPHER on genome-
wide scan of disease genes, which can be used to guide the
selection of candidates for association studies without any
prior knowledge. This is done by using the whole genome as
the test set. Note that the concordance score can only be
computed for genes in the protein network, which we termed
the ranked genome. We ﬁrst use the leave-one-out cross-
validation, and then check the power of the model to detect
disease genes ab initio, i.e. without any known disease genes
for the query phenotype (see Materials and methods). This is
of great importance because no causative genes have been
identiﬁed for half of the OMIM phenotypes (McKusick, 2007).
In terms of the leave-one-out cross-validation, in 153 of 1444
cases CIPHER-SP successfully predicts the known disease
genes from the 8919 genes in the protein network, with a
precisionof 0.106.Interms oftheabinitio prediction,CIPHER-
SP successfully predicts 140 cases, yielding a precision of
Figure 2 Performance of CIPHER on linkage intervals and the whole genome. (A) Score threshold plotted against precision. (B) The precision-recall curve when
score threshold varies. (C) The percentage of known disease genes contained in the top-ranked proportion of genes in the ranked genome. The zoom-in plot shows
details of the curve in top 5% of the ranked genome.
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our model does not rely on known disease genes of the same
phenotype very much and is effective in predicting disease
genes for phenotypes without any known genetic origins. For
CIPHER-DN, precisions are even higher (0.114 and 0.109,
respectively). The curve in Figure 2C summarizes CIPHER-
SP’s ability to enrich disease genes within top-ranked
candidates.Speciﬁcally,fortheleave-one-outcross-validation,
our model correctly ranks 88.8, 71.5, and 50% of the known
diseasegenes within top 50, 10, and 1% of the rankedgenome,
respectively.
These benchmark tests show that CIPHER-DN generally
achieves higher precision than CIPHER-SP, but later (in Case
study section) we will see that it is less powerful in detecting
novel plausible susceptibility genes, potentially because non-
disease proteins are less likely to interact with disease
proteins. Moreover, we ﬁnd that most (52%) of the genes in
the ranked genome do not have a DN involved in any disease,
thus no concordance score can be calculated by CIPHER-DN.
On the other hand, by taking indirect connections into
consideration, CIPHER-SPcan uncover potential susceptibility
genes that are less studied. Therefore, we will mainly focus on
CIPHER-SP in the following sections.
Comparison with other methods
Various methods (Perez-Iratxeta et al, 2002; Turner et al, 2003;
van Driel et al, 2003; Adie et al, 2005; Aerts et al, 2006; Franke
etal,2006;Otietal,2006;Lageetal,2007)havebeenproposed
for prioritizing candidate genes,but fewof them have reported
the precision within their publications. Traditionally, the
power of these methods is measured by their ability to enrich
known disease genes over random selection, say, fold
enrichment. Lage et al (2007) shows that previous methods
for prioritizing candidate genes in linkage interval generally
achieve average fold enrichment between 3.8 and 23.1, while
our method yields 53.5-fold enrichment. For genome-wide
prediction, only two other methods (Freudenberg and Prop-
ping,2002;Gaultonetal,2007)havebeenappliedtothewhole
genome, achieving the fold enrichment of 14.7 and 67,
respectively. In contrast, CIPHER-SP can approach average
enrichment of 954.4 and 864.7 for the leave-one-out cross-
validation and the ab initio prediction, respectively. For
CIPHER-DN, the enrichment are 1016.8 and 972.2, respec-
tively. Therefore, CIPHER signiﬁcantly outperforms all these
methods in terms of the fold enrichment, both in linkage
intervals and the whole genome.
Of these methods, the Bayesian predictordeveloped by Lage
et al (2007) uses the same types of input (phenotype similarity
and molecular interaction) as CIPHER, and it prioritizes
candidate genes by using similar phenotypes associated with
theﬁrstneighbors.Itachievesaprecisionof0.45andarecallof
0.21 at the default score threshold of 0.1, leading to a fold
enrichment of 23.1 (Lage et al, 2007). Only part of the
benchmark cases can be obtained, which contains 218 gene–
phenotype associations overlapped with our benchmark data.
CIPHER correctly identiﬁes 133 of the 218 associations,
yielding a precision of 61.01%, signiﬁcantly outperforming
the Bayesian predictor (45%). Further, a comparison for the
precision-recall curve of the Bayesian predictor (Figure 2a in
Lage et al, 2007) with that of CIPHER (Figure 2B) again shows
that CIPHER is superior over the Bayesian predictor, especially
for high recall rate, suggesting that CIPHER can achieve higher
accuracy and can be applied to many more diseases.
Another method of particular interest is ENDEAVOUR (Aerts
et al, 2006), which integrates more than 10 types of genomic
data, including Gene Ontology (GO), PPIs, gene expression,
literature, and even disease probability predicted from other
prioritizingmethods.Onemayexpectthatbyintegratingmany
more types of data sources, ENDEAVOUR would yield better
performance than CIPHER. However, the leave-one-out cross-
validation for 83 causative genes involved in 12 complex
diseases indicates that CIPHER has comparable performance
with ENDEAVOUR (0.542 versus 0.530), despite using much
less data sources. Further, we reason that the use of literature
evidence in this benchmark test would unfairly improve
ENDEAVOUR’s performance because these literatures may
include direct evidence that reports the association between
the gene and the disease. After removing literature evidence,
the precision of ENDEAVOUR lowers to 0.434.
Confounding factor, bias, and robustness
Onepossible concern is the potential confounding factor in the
benchmarkingprocedure.Forgenesassociatedwithmorethan
one phenotype (796 out of 1444 genes in this study), it is
relatively easy for the leave-one-out cross-validation to
identify the correct gene. Situation where a known causative
gene is later found to be associated with other phenotypes is
quite possible, as suggested in the OMIM database, in which
on average a gene is related to 1.7 phenotypes (McKusick,
2007). Nonetheless, to assess the possible loss of power in
identifying novel genes undiscovered in any other phenotype
before,wecompletelyremoveallotherphenotypessharingthe
same causative gene under benchmarking. The same leave-
one-out cross-validation yields a precision of 0.3179. Though
decreased, it represents a 34.6-fold enrichment over random
selection, still much better than other methods (a 50%
increaseoverthesecondbestmethoddiscussedinthisarticle).
Moreover, it is argued that the protein network we used
might be biased toward disease proteins (Oti et al, 2006; Xu
and Li, 2006). An examination of the HPRD database shows
that indeed disease proteins have more interaction partners
than other proteins (10.28 compared to 7.30). However, it is
difﬁcult to show conclusively whether this bias is due to
investigators’ preferential interest in disease-related proteins,
or the intrinsic property of disease proteins (see discussion in
Oti et al, 2006; Xu and Li, 2006; Fraser and Plotkin, 2007).
Nonetheless, to assess whether CIPHER critically relies on this
bias, we import about 12000 additional interactions among
non-disease proteins from OPHID (Brown and Jurisica, 2005)
to eliminate the bias. PPIs in OPHID are predicted from high-
throughput screen results of model organisms, thus are less
biasedtoward human disease. Benchmark test on artiﬁcial loci
using the denser protein network yields a precision of 0.4521
for CIPHER-SP, only slightly lower than the original precision
0.491. Therefore, though current protein network might be
biased toward disease proteins, our model does not rely on
such bias to predict disease genes.
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the noise in PPIs data set—the importing of B1/3 less reliable
interactions does not undermine the power much. We further
test this hypothesis by substituting HPRD with the entire
OPHID data set, whose size is comparable to HPRD (see
Materials and methods). Using the leave-one-out cross-
validation on random control, CIPHER-SP achieves a compar-
able precision of 0.33. Although slightly lower than the
performance on HPRD (0.445), the precision is still much
higher (at least 43% higher in terms of the fold enrichment)
than those of most other disease gene prioritization methods
and the random selection. Therefore, we have shown our
method can accurately identify disease genes using noisy data
that are not speciﬁcally generated for the purpose of
investigating human diseases.
We also ﬁnd that our method is robust to noise in the
phenotype similarity data. We introduce noise into the
phenotype similarity score to assess the robustness of our
method to the potential imprecision of phenotype scores.
Results (Supplementary Figure S1) show that our method
achieves a precision above 0.35 even if the phenotype score
contains up to 30% noise, indicating that our method is
relatively insensitive to noise in phenotype score.
Case study: breast cancer
To demonstrate CIPHER’s ability in uncovering known disease
genes and predicting novel susceptibility candidates, we
present a case study for breast cancer, which is the most
commonly occurring cancer among women and accounts for
22% of all female cancers. Known susceptibility genes,
including BRCA1 (Miki et al, 1994) and BRCA2 (Wooster
et al, 1995), can only explain less than 5% of the total breast
cancer incidence and less than 25% of the familial risk,
suggesting that many susceptibility genes remain to be
discovered (Oldenburg et al, 2007). The overview section of
breast cancer (MIM 114480) in OMIM gives a list of 22
susceptibilitygenes(May,2007),16ofwhicharecharacterized
in the protein network data. We ﬁrst examine the results of the
genome-wideabinitio prioritization.ForCIPHER-SP,itassigns
highrankstomostoftheknownbreastcancercausativegenes,
with 10 out of these 16 genes ranked in top 300 of the ranked
genome (Table I). This is statistically signiﬁcant compared to
uniform distribution of disease gene ranks (P¼1.0 10
 11,
Fisher’s exact test, one sided) and 300 is a reasonable number
to be included in a high-resolution single nucleotide poly-
morphism (SNP) association study for a complex disease in
humanpopulation (Gaulton et al, 2007). CIPHER-DN performs
even better on these 10 genes, all ranked within top 49.
Next we checked whether our method can predict novel
susceptibility genes that were identiﬁed recently. We ﬁnd that
15 genes suggested as novel breast cancer susceptibility genes
by literatures are ranked relatively high (top 10%) in a total
of 8919 candidates by CIPHER-SP ab initio (Supplementary
Table S2). Eight of them (GGA1, CENTG1, NCOA6, ADAM12,
GAB1, ITGA9, MAP3K6, and MYOD1) are reported to mutate
at signiﬁcant frequencies in breast cancer cells and are likely
to be responsible for driving the initiation, progression, or
maintenance of the tumor (Sjoblom et al, 2006; Wood et al,
2007). The protein kinase AKT1, ranked at 27, is a novel
oncogene,andrecentlyatransformingmutationwasidentiﬁed
in human breast, colorectal, and ovarian cancers (Carpten
et al, 2007). The cell cycle checkpoint gene RAD9, ranked at
130, is a novel oncogene activated by 11q13 ampliﬁcation and
DNA methylation in breast cancer (Cheng et al, 2005). MDM2,
ranked at 182, has a SNP in promoter region that was found to
accelerate breast and ovarian carcinogenesis in BRCA1 and
BRCA2 carriers of Jewish Ashkenazi descent (Yarden et al,
2007). Eestrogen receptor beta (ESR2), ranked at 336, was
recently suggested to be associated with increased risk in
sporadic breast cancer patient by haplotype analysis (Maguire
et al, 2005). WRN, ranked at 340, is a Werner Syndrome
causative gene recently found to be associated with breast
tumorigenesis (Ding et al, 2007). IKBKE, ranked at 793, is
identiﬁed by integrative genomic approaches as a breast
canceroncogene(Boehmetal,2007).RAD50, rankedat799,is
suggested to have effect on genomic integrity and suscept-
ibility to breast cancer (Heikkinen et al, 2006). CIPHER-DN
fails to assign ranks to some of these genes.
Further,weexaminegenefunctionandpathwayenrichment
among the top 100 breast cancer-related genes. This is carried
out usingDAVID(Dennisetal,2003),byanalyzing enrichment
of GO Biological Process terms (Supplementary Table S3), and
BIOCARTA pathways (Supplementary Table S4). Results show
that those genes are enriched in cell cycle and its regulation,
DNA damage and repair, cell growth/cell death and their
regulation, and estrogen receptor regulation, which agree well
with current knowledge on breast cancer (Oldenburg et al,
2007).
A predicted genetic landscape of human diseases
We use CIPHER to infer genome-wide molecular basis for all
human phenotypesdeﬁned in thephenotype network, tochart
a genetic landscape of human diseases. We ﬁrst compute the
concordance scores between all the 1126 phenotypes and 8919
genes within our data, yielding a matrix of more than 10
million elements. A two-way hierarchical clustering (Eisen
et al, 1998) is then performed to reveal the modular
Table I The ranks and percentages of known breast cancer susceptibility genes
in genome-wide ab initio prioritization
Known disease gene Rank in 8919 candidates
CIPHER-SP % CIPHER-DN %
BRCA1 1 0.01 2 0.02
AR 3 0.03 3 0.03
ATM 19 0.21 4 0.04
CHEK2 66 0.74 19 0.21
BRCA2 139 1.56 49 0.54
STK11 150 1.69 21 0.23
RAD51 174 2.00 36 0.40
PTEN 188 2.10 24 0.26
BARD1 196 2.20 41 0.45
TP53 287 3.22 45 0.50
RB1CC1 798 8.95 6360 71.30
NCOA3 973 10.91 343 3.84
PIK3CA 1644 18.43 367 4.11
PPM1D 1946 21.82 7318 82.04
CASP8 4978 55.81 2397 26.87
TGF1 7116 79.78 3502 39.26
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(Figure 3A). Phenotypes clustered together generally have
similar molecular basis, or share signiﬁcant genetic overlaps.
Phenotypeclustersaremanuallyinspectedandannotatedwith
enriched disease categories on the basis of manual classiﬁca-
tion concerning the physiological system affected (Goh et al,
2007), and gene clusters are annotated with the most enriched
biological process terms of GO, according to DAVID (Dennis
et al, 2003).
The modularity of disease landscape is manifested as many
isolatedandhighlyscoredblocks ormodules,eachcomprising
a set of functionally related genes implicated in a set of
genetically overlapped phenotypes. For example, the pink
circled region in Figure 3A indicates a module composed of a
Figure3 Modular organizationofthe predictedgeneticlandscape ofhumandiseases.(A)Hierarchical clustering oftheconcordance scoresbetween8919 genesand
1126 phenotypes. The color of each cell represents the concordance score of a phenotype (column) and a gene (row), where red/blue indicates high/low concordance
score. Phenotype clusters are annotated with enriched disease categories (bottom) and gene clusters are annotated with the most enriched biological process terms of
GO(right).Thepinkcircledregionindicatesamodulecomposedofagenesetofmusclecontractioninvolvinginasetofcardiovasculardiseases.(B)Zoom-inplotofpart
of the pinkcircled region, involving 8cardiovasculardiseases and 26 highlyrelated genes. VT-S: ventricular tachycardia, stress-inducedpolymorphic [MIM 604772]; VT-
I: ventricular tachycardia, idiopathic [MIM 192605]; HB: heart block, non-progressive [MIM 11390]; BS: Brugada syndrome [MIM 601144]; LQT3: long QT syndrome-3
[MIM 603830]; SSS-R: sick sinus syndrome, autosomal recessive [MIM 608567]; SSS-D: sick sinus syndrome, autosomal dominant [MIM 163800]; VF-I: ventricular
ﬁbrillation, idiopathic [MIM:603829]. (C) Protein interaction network of the 26 genes (circles) and 2 other genes (diamond) linking GNB4 to the main component.
Network-based global inference of disease genes
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involving in a set of cardiovascular diseases. Figure 3B shows
a continuous part of this region, in which 8 cardiovascular
diseases are highly related to 26 genes, nearly all of which are
within a subnetwork connected by PPIs between themselves
(Figure 3C). Another interesting module comprises a set of
ophthalmological diseases and genes with function of sensory
perception of light stimulus. As shown in Figure 3A, one
disease set may be related to several gene sets, e.g.
immunological diseases are related to genes with function
enriched in blood coagulation and defense response. On the
otherhand, onegene set may berelatedto severaldiseasesets,
e.g. muscle contraction genes are also highly related to
muscular diseases, apart from cardiovascular diseases.
It is hoped that various analyzing methods devised for gene
expression proﬁle can also be used to extract useful informa-
tion from this predicted disease landscape, for example, the
identiﬁcation of differentially expressed genes (Hatﬁeld et al,
2003), and gene set enrichment analysis (Subramanian et al,
2005).
We further chart a much more comprehensive landscape for
human diseases, involving more than 14000 human proteins
and more than 5000 phenotypes. The extended human protein
network with more than 70000 interactions is assembled from
three curated databases (see Materials and methods). On the
basis of this protein network, genome-wide prioritization is
carried out for existing phenotypes within the phenotype
network, including those without known genetic basis at the
moment. All these data are publicly available online (http://
bioinfo.au.tsinghua.edu.cn/cipher, also see Supplementary
dataset S5 for results of top 100 genes). We hope that the
predicted genetic landscape will facilitate future discovery of
disease genes. To ﬁnd out true causative genes from the
prioritized list, one can select high-rank genes and test their
causality using appropriate experimental protocols. For
example, one can sequence the putative causative genes and
check for DNA mutations in sufﬁcient size of patient samples
(Carpten et al, 2007). Or, for conﬁrmation of putative
oncogenes, one can seek for mutations or ampliﬁcation/
translocation of the genes in primary tumors, and also gather
experimental evidences that demonstrate critical roles of the
putative genes for cancer cell’s viability or proliferation
(Boehm et al, 2007).
Exploring gene cooperativity
Most genes underlying common (or complex) diseases are
non-Mendelian. These genes show very little effects indepen-
dently but may interact with each other and behave
cooperatively to predispose to disease. Various sophisticated
algorithms are proposed to uncover these joint effects in
population association studies (Ritchie et al, 2001; Zhang and
Liu, 2007). Here, we show that CIPHER provides another
interesting way to address this issue. Note that the basic
assumption of our model parallels the regression model in
transcription factor-binding motif discovery from gene expres-
sion data, which assumes additivity of the contributions from
different transcription factors to target gene expressions
(Bussemaker et al, 2001). The model ﬁts the expression data
using motif occurrence counts in gene promoter regions,
which has the same form as equation (3). Various methods
have been proposed to address the problem of cooperativity
between transcription factors such as MARSMotif (Das et al,
2004), which builds response function in terms of nonlinear
component functions and their products. It is able to identify
known functional motifs and their cooperative combinations.
Assuming the same nonlinear behavior exists among genes in
terms of causing complex disease, we run MARSMotif on top
100 breast cancer-related genes of ab initio genome-wide
scoring, and identify 3 signiﬁcant gene pairs that best explain
the variation of the phenotype similarities (Supplementary
TableS6).Interestingly,thoughnoneofthethreepairsofgenes
interact directly with each other, all of them are linked to each
other through BRCA1 and/or BRCA2 by PPIs, and form a star-
like subnetwork (Figure 4A). All the six genes are recorded in
OMIM, and most of them have already been related to breast
cancer. For example, BRCC3 [MIM 300617] is the third subunit
ofBRCA1/BRCA2-containedcomplexBRCC(Dongetal,2003),
Figure 4 BRCA1 subnetwork. (A) Six genes found to participate in three interacting pairs by MARSMotif are linked to BRCA1/BRCA2 by protein–protein (pp)
interactions. (B) Hierarchical clustering of the six genes according to their similarity of function (Gene Ontology Biological Process annotation).
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DNA damage. JUNB [MIM 165161], suggested by MARSMotif
to cooperate with BRCC3, is an oncogene recently discovered
to play important role in biological behavior of breast cancer
(Langer et al, 2006). The biological interpretation for their
cooperativity is unclear. One possible explanation is the
between-pathway hypothesis (Kelley and Ideker, 2005) that
the two genes within an interacting pair come from different
pathways compensating each other, with BRCA1 as the
communication center, or the pivot node (Ulitsky and Shamir,
2007). Interestingly, we ﬁnd indeed these six genes are
clustered into two groups with interacting genes being
separated in different groups. (Figure 4B; clustering is based
on similarities of GO annotations calculated by GOstats
package in Bioconductor; Gentleman et al, 2004).
Discussion
The success of this model, CIPHER, can be attributed to a
combination of several aspects. First, we take the advantage of
large-scale phenotype similarity information. Second, and
maybemoreimportantly,ourmodelexploitsthemodularityof
genetic diseases more comprehensively. For each candidate
gene–phenotype association, the concordance score makes
sufﬁcient use of the information implicated in the entire
protein network and phenotype network, rather than merely
the local environment. In contrast, both ENDEAVOUR and the
Bayesian predictor consider only direct interacting proteins
andphenotypesassociatedwith them.Theglobalnatureofthe
concordance score makes CIPHER robust to the imprecision of
phenotype similarity scores and suffer less from the false
positives and false negatives in the current protein network.
There are three potential applications of the predicted
genetic landscape of human diseases. First, for candidate
association studies, our results can be used to guide the
selection of candidate genes in a less biased manner.
Previously, the selection of candidate genes suffers from the
poor prior knowledge about the biology of the disease, and is
limited by the scope of experts. The global nature of our
method suffers less from such limitation, and candidates are
selected in the context of protein interaction network, which
would facilitate the interpretation of the results. Second, the
genome-wide prioritization results can also be integrated into
weighted/hierarchical genome-wide association studies by
mapping concordance scores to SNPs according to their
genomic locations. Recent studies (Chen and Witte, 2007;
Ionita-Laza et al, 2007) show that by quantitatively incorpor-
ating prior information about SNPs, one may clearly distin-
guish true causal variants from noise. Third, the predicted
disease landscape provides a preliminary but systematic view
of genetic overlaps between different disease phenotypes,
which has immediate practical implications for the design of
gene-mapping studies (Rzhetsky et al, 2007; Oti et al, 2008).
The need for large sample size and the high cost in collecting
patient samples have long been a great challenge for genome-
wide gene-mapping studies (Hirschhorn and Daly, 2005).
Sample pooling strategy, which combines case–control from
several genetically overlapped complex diseases, is promising
tohandle thisproblem.Here, thediseaselandscapemoves one
stepforwardtoshowspeciﬁcallyonwhichpartsofthegenome
they may overlap, suggesting possible hypothesis on patho-
genesis of syndrome.
Certainly, our approach can be improved in the following
directions. First, our method is limited to genes with known
protein interactions (about one-third of the entire human
genome). Further expanding the protein network to embrace
less reliable protein interactions (such as the OPHID network)
or non-physical functional associations (Franke et al, 2006)
may increase the power to detect less-studied disease genes in
practice, as suggested in the study of yeast mutant phenotypes
(McGary et al, 2007). Second, our method suffers from the
imprecision and subjectiveness in quantifying phenotype
similarity. The continuing endeavor for standardizing and
quantifyingphenotypic descriptionwouldfurtherenhanceour
method (Biesecker, 2005). Third, like other methods for
disease gene ﬁnding, our method cannot tell where the
causative genetic variants are in high-rank genes. With the
recent progress in the prioritization of candidate genetic
variants for human diseases (Jiang et al, 2007), it is expected
that by prioritizing candidate genes and genetic variants at the
same time, the two may beneﬁt each other and facilitate the
discovery of disease genes and causative genetic variants
therein.
Our method illustrates well the power of the integration of
different types of networks. We suggest that the ongoing large-
scale mapping of human interaction networks (Aloy, 2007)
and systematic collection of human phenotypic data (Freimer
and Sabatti, 2003) are valuable for biomedical research, and
the increasing coverage and quality of human interaction
network, as well as more standardized and objective
phenotype descriptions will facilitate the discovery of new
disease genes. We also believe that the global concordance
analysis may provide ways to better understand the associa-
tion of different diseases, a holistic rule is also held in
traditional Chinese medicine (Li et al, 2007). Taken together,
our preliminary study on modeling rules connecting pheno-
type and genotype networks is one step further toward the
emerging ﬁeld of ‘network medicine’ (Barabasi, 2007).
Materials and methods
Data sources
Weobtain34364manuallycuratedPPIsbetween8919humanproteins
from the HPRD database (Peri et al, 2003). We also obtain 33049
predicted human PPIs between 7185 (4116 are absent from HPRD)
proteins from the OPHID database (Brown and Jurisica, 2005), which
is built by mapping PPIs from high-throughput screen of model
organisms to human. The extended protein network combines HPRD,
OPHID and two other curated PPI databases: BIND (Bader et al, 2003)
and MINT (Chatr-aryamontri et al, 2007), yielding a network of 72431
unique pairwise binary interactions between 14433 human proteins.
We use the phenotype deﬁned inOMIM database(McKusick, 2007).
The phenotype similarity scores are obtained from van Driel et al
(2006), calculated by text mining of OMIM phenotype records using
Medical Subject Headings (MeSH) terms (Lowe and Barnett, 1994).
Each phenotype is characterized by a vector of standardized and
weightedphenotypicfeaturetermsmappedfromcorrespondingOMIM
records (full text and clinical synopsis ﬁelds) using MeSH terms (the
anatomy (A) and disease (C) sections). The similarity score between
two phenotypes is determined by the cosine of their feature vector
angle (Brunner and van Driel, 2004). The reliability of the phenotype
similarity score has been tested (van Driel et al, 2006), showing that
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measures of gene functions. The ﬁnal phenotype network contains
pairwise similarity scores for 5080 OMIM phenotypes, covering the
majority of recorded human phenotypes.
The gene–phenotype associations are deﬁned in OMIM and are
automatically extracted from BioMART (previously known as En-
sMart; Kasprzyk et al, 2004). We ﬁlter out phenotypes that are not
included in our phenotype network, as well as phenotypes having no
causative genes in our protein network. In total, we collect 1444 cases
(validated gene–phenotype associations) involving 1126 phenotypes
in HPRD network, and 2002 cases involving 1421 phenotypes in the
extended protein network. All these data sources are downloaded in
May, 2007.
Regression model and the concordance score
Our model assumes the additivity of the contribution to phenotype
similarity from different disease genes and is deﬁned as
Spp0 ¼ Cp þ
X
g2GðpÞ
X
g02Gðp0Þ
bpge
 L2
gg0 ð1Þ
Here, Spp0 is the similarity score between a query phenotype p and
another phenotype p0, and Lgg0 is the topological distance between
genes g and g0 on the protein network. G(p) denotes all disease genes
belonging to the phenotype p. The Gaussian kernel e
 L2
gg0 is used to
transfer gene–gene distance to gene–gene closeness. Cp is a constant,
and bpg is the coefﬁcient of this regression model, respectively.
Cp could be explained as the basal similarity between p and other
phenotypes whose causative genes are not connected to those of p in
the protein network, and bpg represents the level of the gene
g contributing to the similarity of the phenotype p to any other
phenotype p0. For practical consideration, we simply assume that this
coefﬁcientisindependentofp0 andg0.Insummary,thismodelassumes
that the similarity of two phenotypes can be explained as the result of
the linearcontribution of theirdisease gene closenessin PPI networks.
We consider two types of neighborhood systems to deﬁne the
topological distance Lgg0, depending on how indirect interaction is
considered: (i) SP, in which Lgg0 is the graph theory SP length between
genesgandg0 intheproteinnetworkand(ii)DN,amodiﬁedversionof
SP, in which Lgg0¼N for indirect neighbor.
To quantify the association between a phenotype and a gene,
we deﬁne the closeness of gene g to phenotype p0 as the summation
of gene–gene closeness from gene g to all disease genes of phenotype
p0,a s
Fgp0 ¼
X
g02Gðp0Þ
e
 L2
gg0
Thus equation (1) can be rewritten as
Spp0 ¼ Cp þ
X
g2GðpÞ
bpgFgp0 ð2Þ
The similarities between the query phenotype p and all n phenotypes
and the closeness between gene g and all n phenotypes are deﬁned as
the phenotype similarity proﬁle and the gene closeness proﬁle,
respectively, and are denoted as vectors Sp¼(Spp1, Spp2,y,Sppn) and
Fg¼(Fgp1, Fgp2,y,Fgpn). Thus, we can extend equation (2) to the
form of
Sp ¼ Cp þ
X
g2GðpÞ
bpgFg ð3Þ
In this linear regression model, we deﬁne the Pearson linear
correlation coefﬁcient as the concordance score
CSpg ¼
covðSp;FgÞ
sðSpÞsðFgÞ
where cov and s mean covariance and standard deviation, respec-
tively. This concordance score measures the consistency between the
position of gene g in the protein network and the variations of
phenotypesimilarityforphenotypepinthewholephenotypenetwork.
It is then used to rank all the candidate genes for a speciﬁc phenotype.
NotethatinCIPHER-DN,forgenesthatdonotlinktoanydiseasegenes
directly, Fg¼0, and thus s(Fg)¼0 and the CSpg cannot be computed. In
such scenario, we set CSpg¼ 1, and these genes will be ranked at the
tail.
Benchmark tests
A leave-one-out cross-validation procedure is used to assess the
performance of CIPHER. In this procedure, we remove the direct link
between true disease gene g and phenotype p, and see if the method
can recover this link (rank gene g at the top of the N test genes). This is
carried out by taking known disease gene g as unknown when
calculating Fgip, the closeness from test gene gi to query phenotype p.
Speciﬁcally, we compute a gene–gene distance matrix, together with a
gene–phenotypeclosenessmatrixbeforethebenchmarktest.Foratest
caseinvolvingphenotypep,causativegenegandN–1controlgenesg1,
g2,y,gN 1, we modify the gene–phenotype closeness from all N test
genestophenotypep,bysubtractingthe closenessbetweengenegand
all N test genes (including gene g itself). This is equivalent to taking
gene g as a non-causative gene when calculating the gene–phenotype
closeness matrix. For ab initio prediction, we use leave-k-out cross-
validation done in a similar way, where k denotes the number of
known disease genes for the query phenotype. For phenotypes with
more than one known causative genes, we modiﬁed the deﬁnition of a
successful prediction: for a test case (p, g) in which p has k known
diseasegenes,ifgenegisamongthetopk-rankedgenes,weconsiderit
a successful prediction.
Fold enrichment
If a method successfully ranks known disease genes in the top m%o f
all candidate genes in n% of the linkage intervals, there is a n/m-fold
enrichment on average. For example, when testing on artiﬁcial
interval, our method successfully ranks known disease genes in the
top 0.917% (top 1 of 109) of all test genes in 49.1% (709 of 1444) test
cases, achieving a fold enrichment of 53.5 on average.
Comparison with ENDEAVOUR
ENDEAVOUR (version 1.39) is downloaded from the website: http://
homes.esat.kuleuven.be/~bioiuser/endeavour/endeavour.php. We
run it on our data set. To provide sufﬁcient training for ENDEAVOUR,
we include phenotype with at least six causative genes from CIPHER’s
benchmark set. After automated mapping of identiﬁers, 83 genes
involved in 12 phenotypes are recognized by ENDEAVOUR. For each
disease gene, other genes from the same phenotype are used to
construct the training set. The test set consists of the causative gene
and 108 ﬂanking genes, as used by CIPHER. ENDEAVOUR is trained
andbenchmarkedbyleave-one-outcross-validationonthetrainingand
test sets, and then the resulting ranks are compared with CIPHER.
Eliminating bias in the protein network
The average degree of disease proteins and others in current protein
network are 10.28 and 7.30, respectively. To eliminate this bias, we
import additional interactions among non-disease proteins from
OPHID to elevate the average degree of non-disease proteins, while
maintaining the size of the protein network. In total, about 12000 PPIs
are extracted, which increase the average degree of non-disease
proteins to 10.30, hence eliminating the bias.
Assessing the inﬂuence of noise in phenotype
similarity score
New phenotype scores are generated by combining the original score
with noise:
scorecombined ¼ scoreoriginal ð1   aÞþscorenoise a
where the noise scorenoise is generated from a uniform distribution
U(0,1), and a is a coefﬁcient ranging from 0 to 1, indicating the
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precisionofCIPHER(testedonrandomcontrol)changeswhenavaries
from 0 to 1 can be found in Supplementary Figure S1.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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